Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 5/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.52 |
| ▸ | CDC42BPB | Q9Y5S2 | 5/20 | 0.52 |
| ▸ | CLK2 | P49760 | 10/20 | 0.49 |
| ▸ | CLK3 | P49761 | 9/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.49 |
| ▸ | WNT1 | P04628 | 5/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.42 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17564330 | 0.92 | CLK2 (0.52) | ROCK2ROCK1CDC42BPBCLK2CLK3 | |
| SCHEMBL17639444 | 0.90 | CLK2 (0.55) | ROCK2ROCK1CDC42BPBCLK2CLK3 | |
| SCHEMBL17564294 | 0.90 | ROCK1 (0.48) | ROCK2ROCK1CDC42BPBCLK2CLK3 | |
| SCHEMBL17564272 | 0.88 | ROCK2 (0.49) | ROCK2ROCK1CDC42BPBCLK2CLK3 | |
| SCHEMBL17564275 | 0.88 | WNT1 (0.52) | ROCK2ROCK1CDC42BPBCLK2CLK3 | |
| SCHEMBL17564284 | 0.87 | WNT1 (0.48) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17564286 | 0.87 | WNT1 (0.48) | CLK2CLK3DYRK1AWNT1TGFBR1 | |
| SCHEMBL17564280 | 0.87 | WNT1 (0.51) | ROCK2ROCK1CDC42BPBCLK2CLK3 | |
| SCHEMBL17569374 | 0.87 | DYRK1A (0.55) | ROCK2ROCK1CDC42BPBCLK2CLK3 | |
| SCHEMBL17564281 | 0.86 | WNT1 (0.54) | ROCK2ROCK1CDC42BPBCLK2CLK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-04-25 | — | — | US | disclosed |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-05-24 | — | — | US | disclosed |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2018-05-24 | — | — | US | disclosed |
| US-9758531-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-9758531-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160068550-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
| US-20160068550-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | ROCK2 1650/4885ROCK1 969/4885CDC42BPB 199/4885 |
| US-20160068550-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | ROCK2 1650/4885ROCK1 969/4885CDC42BPB 199/4885 |
| US-20180141963-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | ROCK2 1650/4885ROCK1 969/4885CDC42BPB 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.